A US hospital runs out of a chemotherapy drug.
A child's cancer treatment is on the line.
👉 Regulators pick up the phone… and call India.
That's not a hypothetical. That's exactly what happened when Baxter's factory hit trouble and the cancer drug Ifosfamide vanished from American shelves.
And it just exposed one of the strangest paradoxes in global pharma.
Here's the wild part.
Indian companies have the FDA approvals.
They have the factories.
They have the regulatory paperwork stacked and ready.
They're just… walking away.
Why?
Because the math no longer works.
The new USP 2025 Annual Drug Shortages Report lays it bare:
💸 Generic injectables in shortage: $20/unit. Not in shortage? $169.
💊 Oral solids in shortage: $3/unit. Stable supply? $8.
🚪 Drug discontinuations jumped 60% to 170 products — the highest since 2019.
⏳ Average shortage now lasts 5.3 years, up from 4.3.
When a vial sells for less than a cup of coffee, no one wants to make it.
So they stop.
India isn't a side player here. It's the spine.
🇮🇳 63% of all oral solid drug volume shipped to the US
💉 16% of injectable volume
🧪 Primary API supplier for 7 shortage drugs
🔗 44 of 75 shortage drugs depend on India or China for key starting materials
Take cefotaxime, a frontline antibiotic for serious infections.
Its API? Made entirely in India.
Its starting materials? Almost entirely from China.
It's been in shortage for over a decade.
Indian manufacturers are caught in a vise.
On one side: aggressive price erosion from US buyers who want generics cheaper every year.
On the other: rising FDA compliance costs that make every facility upgrade a multi-million dollar bet.
So what do rational businesses do?
They exit the categories that bleed them.
And suddenly, one factory hiccup in Indiana means a child in Boston can't get chemo.
America spent decades demanding the cheapest possible pills.
It got them.
It also got a supply chain so thin, so concentrated, and so unprofitable… that the people making the medicine are quietly closing the door.
Hospitals are now rationing.
Treatments are being delayed.
Doctors are switching to second-best alternatives.
Cheap medicine isn't cheap.
It just hides the cost somewhere else — usually in a hospital bed.
That's all for now!
